NCT01731002 - Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure | Biotech Hunter

Enrollment

224

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Ocular HypertensionOpen Angle Glaucoma

Interventions

DRUG

AR-13324 Ophthalmic Solution 0.01%

Administered to study eye, once daily (QD) in the evening (PM) for 28 days

DRUG

AR-13324 Ophthalmic Solution 0.02%

Administered to study eye, QD in the PM for 28 days

DRUG

Latanoprost ophthalmic solution 0.005%

Administered to study eye, QD in the PM for 28 days

Trial Locations (22)

11563

Ophthalmic Consultants of Long Island, Lynbrook

14618

Rochester Ophthalmological Group, Rochester

19107

Wills Eye Hospital, Philadelphia

21078

Seidenberg Protzko Eye Associates, Havre de Grace

21209

Alan L Robin, M.D., Baltimore

23502

Virginia Eye Consultants, Norfolk

27262

Michael E. Tepedino, M.D., High Point

28210

Charlotte Eye Ear Nose and Throat, Charlotte

30076

Coastal Research Associates, LLC, Roswell

30260

Clayton Eye Center, Morrow

40217

Taustine Eye Center, Louisville

49085

Great Lakes Eye Care, Saint Joseph

66204

Bradley Kwapiszeski, MD, Shawnee Mission

74104

The Eye Institute, Tulsa

78731

Texan Eye, Austin

Medical Center Ophth. Associates, San Antonio

79902

Cataract & Glaucoma Center, El Paso

90301

United Medical Research Institute, Inglewood

90701

Kenneth Sall, M.D., Artesia

92064

Centre For Health Care, Poway

92657

Aesthetic Eye Care Institute, Newport Beach

94954

North Bay Eye Associates, Petaluma